(UHT) Universal Health Realty - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US91359E1055
Stock: Hospital, Medical Office, Behavioral Facility, Emergency Department, Childcare
Total Rating 46
Risk 80
Buy Signal -0.60
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 7.38% |
| Yield on Cost 5y | 6.39% |
| Yield CAGR 5y | 1.40% |
| Payout Consistency | 100.0% |
| Payout Ratio | 2.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 22.4% |
| Relative Tail Risk | 1.17% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.55 |
| Alpha | 6.74 |
| Character TTM | |
|---|---|
| Beta | 0.257 |
| Beta Downside | 0.227 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.42% |
| CAGR/Max DD | -0.05 |
Description: UHT Universal Health Realty December 26, 2025
Universal Health Realty Income Trust (NYSE: UHT) is a Health-Care REIT that owns and leases a diversified portfolio of 76 properties across 21 U.S. states, including acute-care hospitals, behavioral health facilities, specialty centers, medical office buildings, freestanding emergency departments, and childcare centers.
Key operating metrics as of the latest filing show an occupancy rate of roughly 96% and a dividend yield near 7.5%, reflecting the REIT’s strong cash-flow generation. The fund’s FY 2023 Funds-From-Operations (FFO) grew about 5% year-over-year, while its leverage ratio (debt-to-FFO) remained modest at ~0.6, indicating a conservative capital structure. Primary sector drivers include the U.S. aging population-projected to add ~10 million seniors by 2030-and the shift toward outpatient and specialty care, which boosts demand for flexible, lease-back-type facilities.
For a deeper dive into UHT’s valuation dynamics and how its risk-adjusted returns compare to peers, you might explore the analytical tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 17.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.00 > 1.0 |
| NWC/Revenue: -252.1% < 20% (prev -243.1%; Δ -8.93% < -1%) |
| CFO/TA 0.09 > 3% & CFO 48.6m > Net Income 17.9m |
| Net Debt (379.6m) to EBITDA (68.1m): 5.57 < 3 |
| Current Ratio: 0.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.9m) vs 12m ago 0.08% < -2% |
| Gross Margin: 94.41% > 18% (prev 0.94%; Δ 9346 % > 0.5%) |
| Asset Turnover: 17.24% > 50% (prev 16.89%; Δ 0.36% > 0%) |
| Interest Coverage Ratio: 1.24 > 6 (EBITDA TTM 68.1m / Interest Expense TTM 31.9m) |
Altman Z'' 4.70
| A: -0.44 (Total Current Assets 118.7m - Total Current Liabilities 369.2m) / Total Assets 568.0m |
| B: 1.51 (Retained Earnings 858.6m / Total Assets 568.0m) |
| C: 0.07 (EBIT TTM 39.6m / Avg Total Assets 576.2m) |
| D: 2.10 (Book Value of Equity 860.8m / Total Liabilities 409.5m) |
| Altman-Z'' Score: 4.70 = AA |
Beneish M -3.11
| DSRI: 0.97 (Receivables 111.8m/114.8m, Revenue 99.4m/98.7m) |
| GMI: 1.00 (GM 94.41% / 94.47%) |
| AQI: 1.00 (AQ_t 0.77 / AQ_t-1 0.77) |
| SGI: 1.01 (Revenue 99.4m / 98.7m) |
| TATA: -0.05 (NI 17.9m - CFO 48.6m) / TA 568.0m) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of UHT shares?
As of February 07, 2026, the stock is trading at USD 42.10 with a total of 56,712 shares traded.
Over the past week, the price has changed by +5.97%, over one month by +5.94%, over three months by +13.48% and over the past year by +14.61%.
Over the past week, the price has changed by +5.97%, over one month by +5.94%, over three months by +13.48% and over the past year by +14.61%.
Is UHT a buy, sell or hold?
Universal Health Realty has received a consensus analysts rating of 5.00.
Therefore, it is recommended to buy UHT.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UHT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43 | 2.1% |
| Analysts Target Price | 43 | 2.1% |
| ValueRay Target Price | 45.3 | 7.6% |
UHT Fundamental Data Overview February 03, 2026
P/E Trailing = 30.6589
P/S = 5.4631
P/B = 3.4112
Revenue TTM = 99.4m USD
EBIT TTM = 39.6m USD
EBITDA TTM = 68.1m USD
Long Term Debt = 18.6m USD (from longTermDebt, last quarter)
Short Term Debt = 357.1m USD (from shortTermDebt, last quarter)
Debt = 386.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 379.6m USD (from netDebt column, last quarter)
Enterprise Value = 928.3m USD (548.7m + Debt 386.5m - CCE 6.92m)
Interest Coverage Ratio = 1.24 (Ebit TTM 39.6m / Interest Expense TTM 31.9m)
EV/FCF = 19.08x (Enterprise Value 928.3m / FCF TTM 48.6m)
FCF Yield = 5.24% (FCF TTM 48.6m / Enterprise Value 928.3m)
FCF Margin = 48.96% (FCF TTM 48.6m / Revenue TTM 99.4m)
Net Margin = 18.06% (Net Income TTM 17.9m / Revenue TTM 99.4m)
Gross Margin = 94.41% ((Revenue TTM 99.4m - Cost of Revenue TTM 5.56m) / Revenue TTM)
Gross Margin QoQ = 94.41% (prev 94.41%)
Tobins Q-Ratio = 1.63 (Enterprise Value 928.3m / Total Assets 568.0m)
Interest Expense / Debt = 4.07% (Interest Expense 15.7m / Debt 386.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = 31.3m (EBIT 39.6m * (1 - 21.00%))
Current Ratio = 0.32 (Total Current Assets 118.7m / Total Current Liabilities 369.2m)
Debt / Equity = 2.44 (Debt 386.5m / totalStockholderEquity, last quarter 158.6m)
Debt / EBITDA = 5.57 (Net Debt 379.6m / EBITDA 68.1m)
Debt / FCF = 7.80 (Net Debt 379.6m / FCF TTM 48.6m)
Total Stockholder Equity = 168.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.11% (Net Income 17.9m / Total Assets 568.0m)
RoE = 10.63% (Net Income TTM 17.9m / Total Stockholder Equity 168.9m)
RoCE = 21.13% (EBIT 39.6m / Capital Employed (Equity 168.9m + L.T.Debt 18.6m))
RoIC = 5.79% (NOPAT 31.3m / Invested Capital 540.3m)
WACC = 5.35% (E(548.7m)/V(935.2m) * Re(6.86%) + D(386.5m)/V(935.2m) * Rd(4.07%) * (1-Tc(0.21)))
Discount Rate = 6.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.13%
[DCF Debug] Terminal Value 86.90% ; FCFF base≈46.9m ; Y1≈49.7m ; Y5≈59.1m
Fair Price DCF = 98.96 (EV 1.75b - Net Debt 379.6m = Equity 1.37b / Shares 13.9m; r=5.90% [WACC]; 5y FCF grow 6.66% → 2.90% )
EPS Correlation: -51.95 | EPS CAGR: -49.34% | SUE: N/A | # QB: 0
Revenue Correlation: 89.01 | Revenue CAGR: 4.55% | SUE: N/A | # QB: 0
P/S = 5.4631
P/B = 3.4112
Revenue TTM = 99.4m USD
EBIT TTM = 39.6m USD
EBITDA TTM = 68.1m USD
Long Term Debt = 18.6m USD (from longTermDebt, last quarter)
Short Term Debt = 357.1m USD (from shortTermDebt, last quarter)
Debt = 386.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 379.6m USD (from netDebt column, last quarter)
Enterprise Value = 928.3m USD (548.7m + Debt 386.5m - CCE 6.92m)
Interest Coverage Ratio = 1.24 (Ebit TTM 39.6m / Interest Expense TTM 31.9m)
EV/FCF = 19.08x (Enterprise Value 928.3m / FCF TTM 48.6m)
FCF Yield = 5.24% (FCF TTM 48.6m / Enterprise Value 928.3m)
FCF Margin = 48.96% (FCF TTM 48.6m / Revenue TTM 99.4m)
Net Margin = 18.06% (Net Income TTM 17.9m / Revenue TTM 99.4m)
Gross Margin = 94.41% ((Revenue TTM 99.4m - Cost of Revenue TTM 5.56m) / Revenue TTM)
Gross Margin QoQ = 94.41% (prev 94.41%)
Tobins Q-Ratio = 1.63 (Enterprise Value 928.3m / Total Assets 568.0m)
Interest Expense / Debt = 4.07% (Interest Expense 15.7m / Debt 386.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = 31.3m (EBIT 39.6m * (1 - 21.00%))
Current Ratio = 0.32 (Total Current Assets 118.7m / Total Current Liabilities 369.2m)
Debt / Equity = 2.44 (Debt 386.5m / totalStockholderEquity, last quarter 158.6m)
Debt / EBITDA = 5.57 (Net Debt 379.6m / EBITDA 68.1m)
Debt / FCF = 7.80 (Net Debt 379.6m / FCF TTM 48.6m)
Total Stockholder Equity = 168.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.11% (Net Income 17.9m / Total Assets 568.0m)
RoE = 10.63% (Net Income TTM 17.9m / Total Stockholder Equity 168.9m)
RoCE = 21.13% (EBIT 39.6m / Capital Employed (Equity 168.9m + L.T.Debt 18.6m))
RoIC = 5.79% (NOPAT 31.3m / Invested Capital 540.3m)
WACC = 5.35% (E(548.7m)/V(935.2m) * Re(6.86%) + D(386.5m)/V(935.2m) * Rd(4.07%) * (1-Tc(0.21)))
Discount Rate = 6.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.13%
[DCF Debug] Terminal Value 86.90% ; FCFF base≈46.9m ; Y1≈49.7m ; Y5≈59.1m
Fair Price DCF = 98.96 (EV 1.75b - Net Debt 379.6m = Equity 1.37b / Shares 13.9m; r=5.90% [WACC]; 5y FCF grow 6.66% → 2.90% )
EPS Correlation: -51.95 | EPS CAGR: -49.34% | SUE: N/A | # QB: 0
Revenue Correlation: 89.01 | Revenue CAGR: 4.55% | SUE: N/A | # QB: 0